BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 2014

Becton Dickinson & Co. (BDX) reported strong financial performance in its fiscal year 2014, with total revenues reaching $8.446 billion, a 4.9% increase over the prior year, driven by growth across its Medical and Biosciences segments, particularly in emerging markets and sales of safety-engineered products. The company's operational efficiency improved, with a gross profit margin of 50.9%. A significant development during the year was the announcement of a definitive agreement to acquire CareFusion Corporation for approximately $12.2 billion, a strategic move expected to create a leader in medication management and patient safety solutions, anticipated to close in the first half of calendar year 2015. BD demonstrated solid cash flow from operations, totaling $1.75 billion, which supported its dividend payments and share repurchases, though the latter was suspended in light of the CareFusion acquisition. The company navigated a complex regulatory and economic landscape, including the impact of the Patient Protection and Affordable Care Act's medical device excise tax. Key risks identified include global economic conditions, foreign currency fluctuations, and competitive pressures within the medical technology market. Management expressed confidence in the company's financial position and ability to access capital to fund its strategic objectives, including the significant CareFusion acquisition.